Effect Of HBsAg—positive Expression On Hepatic Carcinoma Recurrence Of Mouse In Immunosuppressive Statiis

[Objective] To establish HBV transgenic mice model of implanted liver cancer, then explore the effect of serum HBsAg-positive expression on tumor recurrence of mouse in immunosuppressive status through immunosuppressive therapy and then providing theoretical basis for application of using HBsAg-positive donor for patients with advanced liver cancer.[Methods] The experiment includes two parts. Part1:to establish mice model of implanted liver cancer:90male Balb/c mice were inoculated with different number of H22tumor cell lines(1*105,1*106,1*107)under the spleen envelope, then carried on immunosuppressive therapy to imitate tumor recurrence after liver transplantation, respectively in one week, two weeks and three weeks after surgery to observe tumor recurrence. Part2:To research the effect of HBsAg-positive liver donor to tumor recurrence after liver transplantation:the experimental group (Group H) selects30HBV transgenic Balb/c mice, and the control group (Group D) selects30normal Balb/c mice, according to the execution time two groups were respectively divided into3groups which included10mice:H1, H2, H3, D1, D2and D3. Developing animal models were as the Part1. After operation all of the mice were given CsA(5mg/Kg/d) and methyl prednisolone sodium succinate (10mg/Kg/d). In postoperative1week,2weeks and3weeks, the mice were put to death. To observe tumor recurrence; to observe tumor organization form using HE staining; to detect liver tissue ICAM-1, VEGF and PCNA using immune histochemical method. The results of group H and group D were analyzed using SPSS15.0statistical analysis software, comparing various indicators of group difference in liver tumor recurrence.[Results] Part1:The recurrence rate of implanted105H22tumor cell after one week was0(0/10), was20%(2/10) after two weeks, and was30%(3/10) after three weeks. The recurrence rate of implanted106H22tumor cell was20%(2/10) after one week, was40%(4/10) after two weeks, and after three weeks was70%(7/10). The recurrence rate of implanted107H22tumor cell was50%(5/10) after one week, was80%(8/10) after two weeks, and was80%(8/10) after three weeks. We successfully established the model of tumor recurrence of mice, and this can be used for more experimental studies. Part2:The tumor recurrence rate was20%in group H1, was50%in group H2, was80%in group H3, was20%in group D1, was40%in group D2and70%in group D3. There was no statistical difference between the experimental group and control group (P>0.05). Liver tissue HE staining of H1and D1group showed occasional focal tumor tissues. HE staining of H2and D2group showed hepatic tumor lesions. H3and D3groups showed diffuse hepatocellular carcinoma. The positive rates of PCNA in the liver tissue were22.2%in H1and22.8%in D1. The positive rates of PCNA were44.2%in H2and43.6%in D2. The positive rates of PCNA were56.8%in H3and53.4%in D3. There is no statistical difference between the two groups. The positive rates of VEGF in the liver tissue were20.8%in H1and17%in D1. The positive rates of VEGF were25.9%in H2and26.7%in D2. The positive rates of VEGF were36.2%in H3and37.3%in D3. There is no statistical difference between the two groups. The positive rates of ICAM-1in the liver tissue were15.4%in H1and14.5%in D1. The positive rates of ICAM-1were23.2%in H2and22.8%in D2. The positive rates of ICAM-1were31.3%in H3and29.4%in D3. There is no statistical difference between the two groups.[Conclusion]1. We can successfully establish the mice model of liver tumor which implant H22tumor cell under spleen envelope.2. Tumor recurrence was positively related to the number of implanted tumor cells.3. By establishing the animal model of tumor recurrence in immunosuppressive status, we confirm that serum HBsAg-positive expression has no significant effect on tumor recurrence.4. By using this animal model to explore the effect of HBsAg-positive donor on tumor recurrence, it can provide theoretical and experimental basis.